FOSUN PHARMA Subsidiary Gains Approval for Levofloxacin Injection

Stock News17:54

Recently, the holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Chongqing Youcare Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration application of Levofloxacin Injection (referred to as "the drug"). The approved indications are for mild, moderate, and severe infections caused by susceptible bacteria, including: (1) hospital-acquired pneumonia; (2) community-acquired pneumonia; (3) acute bacterial sinusitis; (4) acute bacterial exacerbation of chronic bronchitis; (5) complicated skin and skin structure infections; (6) uncomplicated skin and skin soft tissue infections; (7) chronic bacterial prostatitis; (8) complicated urinary tract infections; (9) acute pyelonephritis; (10) uncomplicated urinary tract infections; and (11) inhalational anthrax (post-exposure). The drug is a self-developed chemical product by the group. As of April 2026, the group's cumulative R&D investment for the drug at this stage is approximately RMB 1.94 million (unaudited). According to the latest IQVIA CHPA data, in 2025, the sales of Levofloxacin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan) were approximately RMB 1.057 billion. The approval of this drug for market launch will further enrich the group's product portfolio.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145508249?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 17:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145508249","market":"hk","top_or_hot":-1,"title":"FOSUN PHARMA Subsidiary Gains Approval for Levofloxacin Injection","media":"Stock News","content":"<p>Recently, the holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Chongqing Youcare Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration application of Levofloxacin Injection (referred to as \"the drug\"). The approved indications are for mild, moderate, and severe infections caused by susceptible bacteria, including: (1) hospital-acquired pneumonia; (2) community-acquired pneumonia; (3) acute bacterial sinusitis; (4) acute bacterial exacerbation of chronic bronchitis; (5) complicated skin and skin structure infections; (6) uncomplicated skin and skin soft tissue infections; (7) chronic bacterial prostatitis; (8) complicated urinary tract infections; (9) acute pyelonephritis; (10) uncomplicated urinary tract infections; and (11) inhalational anthrax (post-exposure). The drug is a self-developed chemical product by the group. As of April 2026, the group's cumulative R&D investment for the drug at this stage is approximately RMB 1.94 million (unaudited). According to the latest IQVIA CHPA data, in 2025, the sales of Levofloxacin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan) were approximately RMB 1.057 billion. The approval of this drug for market launch will further enrich the group's product portfolio.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA Subsidiary Gains Approval for Levofloxacin Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA Subsidiary Gains Approval for Levofloxacin Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-21 17:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Recently, the holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Chongqing Youcare Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration application of Levofloxacin Injection (referred to as \"the drug\"). The approved indications are for mild, moderate, and severe infections caused by susceptible bacteria, including: (1) hospital-acquired pneumonia; (2) community-acquired pneumonia; (3) acute bacterial sinusitis; (4) acute bacterial exacerbation of chronic bronchitis; (5) complicated skin and skin structure infections; (6) uncomplicated skin and skin soft tissue infections; (7) chronic bacterial prostatitis; (8) complicated urinary tract infections; (9) acute pyelonephritis; (10) uncomplicated urinary tract infections; and (11) inhalational anthrax (post-exposure). The drug is a self-developed chemical product by the group. As of April 2026, the group's cumulative R&D investment for the drug at this stage is approximately RMB 1.94 million (unaudited). According to the latest IQVIA CHPA data, in 2025, the sales of Levofloxacin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan) were approximately RMB 1.057 billion. The approval of this drug for market launch will further enrich the group's product portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1145508249","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145508249","pubTimestamp":1779357260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Recently, the holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Chongqing Youcare Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK1515":"抗疫概念","BK0012":"证金概念","BK1593":"医美概念股","BK0196":"行业龙头","BK0175":"白马股","BK0188":"融资融券","BK0060":"抗癌","BK0187":"一线龙头","BK0096":"民营医院","02196":"复星医药","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK1191":"制药"},"translate_title":"复星医药子公司左氧氟沙星注射液获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"Recently, the holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Chongqing Youcare Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration application of Levofloxacin Injection (referred to as \"the drug\"). The approved indications are for mild, moderate, and severe infections caused by susceptible bacteria, including: (1) hospital-acquired pneumonia; (2) community-acquired pneumonia; (3) acute bacterial sinusitis; (4) acute bacterial exacerbation of chronic bronchitis; (5) complicated skin and skin structure infections; (6) uncomplicated skin and skin soft tissue infections; (7) chronic bacterial prostatitis; (8) complicated urinary tract infections; (9) acute pyelonephritis; (10) uncomplicated urinary tract infections; and (11) inhalational anthrax (post-exposure). The drug is a self-developed chemical product by the group. As of April 2026, the group's cumulative R&D investment for the drug at this stage is approximately RMB 1.94 million (unaudited). According to the latest IQVIA CHPA data, in 2025, the sales of Levofloxacin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan) were approximately RMB 1.057 billion. The approval of this drug for market launch will further enrich the group's product portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145508249","isCrawlerRequest":true}